10 leading companies forecast to suffer poor Q4 results

Published: 2012-01-12 07:00:00

Updated: 2012-01-12 07:00:00

Ten major pharmaceutical firms are likely to see their fourth-quarter earnings rise a mere 4.2 percent on-year, buffeted by inevitable handling of drug inventories ahead of the massive drug price cuts starting April, Shinhan Investment and Securities said.

By contrast, Green Cross’s sales are ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK